Compile Data Set for Download or QSAR
Report error Found 994 Enz. Inhib. hit(s) with all data for entry = 11341
TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM250092(US9452980, 2 | US10501411, Example 2 | US11697648,...)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM608407(US11697648, Example 3)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM608409(US11697648, Example 5)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM608414(US11697648, Example 10)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM608423(US11697648, Example 18)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM608438(US11697648, Example 30)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM608442(US11697648, Example 33)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM608485(US11697648, Example 69)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM608503(US11697648, Example 85)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM608506(US11697648, Example 88)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM608509(US11697648, Example 91)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM608511(US11697648, Example 93)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM608525(US11697648, Example 94)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM608526(US11697648, Example 95)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM608527(US11697648, Example 96)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM608529(US11697648, Example 98)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM608530(US11697648, Example 99)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM608531(US11697648, Example 100)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM608532(US11697648, Example 101)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM608533(US11697648, Example 102)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM608534(US11697648, Example 103)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM608535(US11697648, Example 104)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM608536(US11697648, Example 105)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM608537(US11697648, Example 106)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM608541(US11697648, Example 110)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM608543(US11697648, Example 112)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM608545(US11697648, Example 114)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM608548(US11697648, Example 117)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM608550(US11697648, Example 119)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM608555(US11697648, Example 124)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM608556(US11697648, Example 125)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM608557(US11697648, Example 126)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM608558(US11697648, Example 127)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM608559(US11697648, Example 128)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM608560(US11697648, Example 129)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM608563(US11697648, Example 132)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM608564(US11697648, Example 133)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM608565(US11697648, Example 134)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM608569(US11697648, Example 138)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM608570(US11697648, Example 139)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM608571(US11697648, Example 140)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM608573(US11697648, Example 142)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM608574(US11697648, Example 143)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM608575(US11697648, Example 144)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM608581(US11697648, Example 150)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM608588(US11697648, Example 157)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM608593(US11697648, Example 162)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM608596(US11697648, Example 165)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM608597(US11697648, Example 166)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM608598(US11697648, Example 167)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

Displayed 1 to 50 (of 994 total ) | Next | Last >>
Jump to: